Vanguard Group Inc. lowered its position in shares of Cambrex Corporation (NYSE:CBM) by 2.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,075,241 shares of the biotechnology company’s stock after selling 63,693 shares during the period. Vanguard Group Inc. owned approximately 9.44% of Cambrex Corporation worth $183,745,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Cambrex Corporation by 0.5% during the second quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after purchasing an additional 20,652 shares during the period. Congress Asset Management Co. MA raised its stake in shares of Cambrex Corporation by 8.7% during the second quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock valued at $77,497,000 after purchasing an additional 103,900 shares during the period. Clearbridge Investments LLC raised its stake in shares of Cambrex Corporation by 34.8% during the first quarter. Clearbridge Investments LLC now owns 971,174 shares of the biotechnology company’s stock valued at $53,463,000 after purchasing an additional 250,662 shares during the period. FMR LLC raised its stake in shares of Cambrex Corporation by 78.2% during the first quarter. FMR LLC now owns 899,086 shares of the biotechnology company’s stock valued at $49,494,000 after purchasing an additional 394,638 shares during the period. Finally, State Street Corp raised its stake in shares of Cambrex Corporation by 7.6% during the first quarter. State Street Corp now owns 742,151 shares of the biotechnology company’s stock valued at $40,858,000 after purchasing an additional 52,638 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/18/vanguard-group-inc-has-183-75-million-stake-in-cambrex-corporation-cbm.html.

In other Cambrex Corporation news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at approximately $5,852,185.92. The disclosure for this sale can be found here. Insiders have sold 28,000 shares of company stock valued at $1,574,880 in the last ninety days. Company insiders own 2.48% of the company’s stock.

Shares of Cambrex Corporation (NYSE CBM) opened at 51.80 on Wednesday. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 18.87 and a beta of 2.28. The stock’s 50 day moving average is $53.21 and its 200-day moving average is $55.53. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95.

Cambrex Corporation (NYSE:CBM) last announced its earnings results on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.76. The firm had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.68 earnings per share. On average, analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current year.

A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $65.67.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.